Vivani Medical rises after appointing former Amylin Pharmaceuticals CEO to its board

Vivani Medical

06/03/2024 14:26

** Shares of drug developer Vivani Medical  VANI.O  rise
4.2% to $2.24 premarket 
    ** VANI appoints former CEO of Amylin Pharmaceuticals,
Daniel Bradbury, to its Board of Directors
    ** Bradbury headed Amylin Pharmaceuticals until its
acquisition by Bristol-Myers Squibb  BMY.N  in 2012 
     ** Appointment comes as VANI prioritizes the development of
its GLP-1 implants for the treatment of obesity and chronic
weight management 
    ** Co last month said that its experimental under-the-skin
drug implant helped reduce weight in obese mice in a
pre-clinical trial, sending its shares up more than five-fold 
    ** Up to last close, stock has risen 97.2% in the last 12
months 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))